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ABSTRACT Autosomal dominant polycystic kidney disease (ADPKD) constitutes the
most inherited kidney disease. Mutations in the PKD1 and PKD2 genes, encoding the
polycystin 1 and polycystin 2 Ca2 ion channels, respectively, result in tubular epi-
thelial cell-derived renal cysts. Recent clinical studies demonstrate oxidative stress to
be present early in ADPKD. Mitochondria comprise the primary reactive oxygen
species source and also their main effector target; however, the pathophysiologi-
cal role of mitochondria in ADPKD remains uncharacterized. To clarify this func-
tion, we examined the mitochondria of cyst-lining cells in ADPKD model mice
(Ksp-Cre PKD1ﬂox/ﬂox) and rats (Han:SPRD Cy/), demonstrating obvious tubular
cell morphological abnormalities. Notably, the mitochondrial DNA copy number and
peroxisome proliferator-activated receptor  coactivator 1 (PGC-1) expression
were decreased in ADPKD model animal kidneys, with PGC-1 expression inversely
correlated with oxidative stress levels. Consistent with these ﬁndings, human ADPKD
cyst-derived cells with heterozygous and homozygous PKD1 mutation exhibited
morphological and functional abnormalities, including increased mitochondrial
superoxide. Furthermore, PGC-1 expression was suppressed by decreased intra-
cellular Ca2 levels via calcineurin, p38 mitogen-activated protein kinase (MAPK),
and nitric oxide synthase deactivation. Moreover, the mitochondrion-speciﬁc an-
tioxidant MitoQuinone (MitoQ) reduced intracellular superoxide and inhibited
cyst epithelial cell proliferation through extracellular signal-related kinase/MAPK
inactivation. Collectively, these results indicate that mitochondrial abnormalities
facilitate cyst formation in ADPKD.
KEYWORDS mitochondrial metabolism, polycystic kidney disease
Autosomal dominant polycystic kidney disease (ADPKD) is a common geneticdisorder that affects 12.5 million people worldwide in all ethnic groups and
accounts for up to 10% of patients on renal-replacement therapy (1, 2). In this disease,
progressive expansion of numerous bilateral renal cysts leads to massive kidney
enlargement and progressive renal failure. ADPKD is caused by mutations in PKD1 or
PKD2, encoding the nonselective Ca2 ion channels polycystin 1 and polycystin 2,
respectively, which regulate Ca2 inﬂux in primary cilia (3). Lowered intracellular
Ca2-related abnormal signals lead to the induced proliferation of cyst epithelial cells
arising from all nephron segments (4–6), which is a key feature associated with cyst
formation. Reduced Ca2 activates Ca2-inhibitable adenylyl cyclase 6 (AC6) and
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increases the cyclic AMP (cAMP) level (7). In turn, enhanced cAMP and protein kinase
A (PKA) signaling upregulates the extracellular signaling-regulated kinase (ERK)
pathway in cells derived from polycystic kidneys (8). In this manner, ERK activation
is known as a hallmark of ADPKD. Furthermore, the vasopressin 2 receptor (V2R)
signaling pathway involves activation of a stimulatory G protein (Gs) followed by
the activation of AC6 and the generation of the secondary messenger cAMP in cyst
epithelial cells; accordingly, a V2R blocker is used for ADPKD treatment (9). Notably,
PKD1/2 deﬁciency impacts a variety of organs in addition to the kidneys, such that
patients often present with extrarenal diseases involving the liver, heart, vascula-
ture, and diverticulum (10).
The two-hit hypothesis is widely accepted in ADPKD cystogenesis, in which germ
line and somatic mutations of two PKD alleles are necessary to initiate renal cyst
formation (11, 12). However, the reason why numerous second hits occur in the
kidneys of ADPKD patients is unclear. Recent clinical studies show that oxidative
stress is present in early ADPKD, even when renal function is preserved (13, 14),
suggesting that increased oxidative stress plays a functional role in cyst formation.
As mitochondrial damage is a main trigger for intracellular superoxide generation,
we hypothesized that PKD1 mutations may occur in tubular cells harboring only a
single wild-type allele in response to oxidative stress, leading to cyst formation.
Therefore, in this study, we investigated the pathophysiological role of mitochon-
dria in ADPKD.
RESULTS
Mitochondrial abnormalities in the kidneys of ADPKD animal models. Ksp-Cre
PKD1ﬂox/ﬂox mice (15), as a rapid progression model of ADPKD, and heterozygous
Han:SPRD Cy (Cy/) rats (16), as a slow progression model of ADPKD, were used to
assess disease-associated mitochondrial abnormalities in the kidney. Mitochondria are
highly dynamic organelles that exhibit ﬁnely tuned and balanced frequencies of fusion
and ﬁssion events to maintain homeostasis under physiological conditions. Alteration
of mitochondrial morphology from an elongated network into small spheres or
short rods is often accompanied by respiratory defects, increased production of
mitochondrial reactive oxygen species ROS (mtROS), and oxidative damage (17),
suggesting that proper mitochondrial morphology might be a protective factor
involved in human disorders associated with mitochondrial DNA (mtDNA) muta-
tions (18, 19). Therefore, we examined kidney tissues by transmission electron
microscopy (TEM). Notably, the mitochondria of kidney cyst-lining cells from 7-day-
old Ksp-Cre PKD1ﬂox/ﬂox mice exhibited intermingled normal and abnormal shapes.
Abnormally shaped mitochondria became swollen with indistinct and damaged
cristae compared with those in normal distal tubular cells from control mice (Fig.
1A). Similarly, mitochondria of kidney cyst-lining cells from 7-week-old Cy/ rats
were more fragmented than those of normal proximal-tubular epithelial cells from
wild-type (/) rats (Fig. 1B).
Changes in mtDNA copy number are also a marker of mitochondrial abnormality
(20). The mtDNA copy number in the kidney tissue of 7-day-old Ksp-Cre PKD1ﬂox/ﬂox
mice was markedly decreased compared to that in control animals (Fig. 2A). Cy/ rats
also showed a copy number decrease at 7 weeks of age, which became more signiﬁcant
at 16 weeks (Fig. 2B). These results suggested that mitochondrial abnormality exists
from an early phase of ADPKD and is related to disease progression.
Peroxisome proliferator-activated receptor  coactivator 1 (PGC-1) acts as a
master regulator of mitochondrial biogenesis by regulating mitochondrial content (21);
therefore, we assessed changes in PGC-1 expression in kidney tissue from ADPKD
model animals to determine whether a lower renal mtDNA copy number was associ-
ated with decreased PGC-1 expression. As expected, PGC-1 protein and mRNA levels
in the kidneys of Ksp-Cre PKD1ﬂox/ﬂox mice (Fig. 2C and D) and 7-week-old Cy/ rats
(Fig. 2E and F) were markedly lower than those in control animals. Subsequent
immunohistochemical (IHC) analysis revealed a signiﬁcant decrease in PGC-1 expres-
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sion speciﬁcally in the kidney cyst-lining cells of ADPKD animals compared to the
noncystic tubules of control animals (Fig. 3A and B), suggesting that mitochondrial
abnormalities were present in the cyst-lining cells of ADPKD models. Reduced PGC-1
levels correlate with both decreased mtDNA copy number and the onset of oxidative
stress (22, 23), and excessive mtROS production is a hallmark of mitochondrial dys-
function (24, 25). Moreover, IHC for the oxidative stress marker 8-hydroxy-2=-
deoxyguanosine (8-OHdG) showed signiﬁcant increases in marker expression in the
kidney cyst-lining cells from Ksp-Cre PKD1ﬂox/ﬂox mice and Cy/ rats (Fig. 3C and D),
indicating that mitochondrial abnormalities likely incite oxidative stress in these cells.
Together with the observed decrease in PGC-1 expression, these results suggest that
mitochondrial abnormalities in the cyst-lining cells of ADPKD kidneys contribute to the
induction of oxidative stress.
Mitochondrial abnormalities in human cyst epithelial cells derived from an
ADPKD patient with a PKD1 homozygous mutation. Our results from ADPKD model
animals indicated that mitochondrial abnormalities may be present in cyst-lining cells.
To investigate the pathogenic effect of mitochondrial abnormalities on cyst epithelial
cells in human ADPKD, we performed in vitro studies using immortalized cyst-derived
cells established from a single cyst obtained from distal cortical tubules collected from
a patient with ADPKD harboring a homozygous PKD1 mutation (WT 9-12) (26) and a
normal human renal cortical tubular epithelial cell (RCTEC) line derived from normal
distal tubule cells (RCTEC-Dolichos biﬂorus agglutin [RCTEC-DBA]). Similar to the in vivo
data, the mtDNA copy number in cyst-derived cells harboring the homozygous PKD1
mutation was signiﬁcantly lower than that observed in normal cells (Fig. 4A). Addition-
ally, PGC-1 protein and RNA expression in WT 9-12 was also reduced relative to that
observed in RCTEC-DBA (Fig. 4B and C). Decreases in mDNA copy number and PGC-1
expression are associated with morphological changes, such as fragmentation, in
FIG 1 Morphological change of mitochondria in ADPKD animal models. (A) Electron microscope image of 7-day-old Ksp-Cre PKD1ﬂox/ mice and Ksp-Cre
PKD1ﬂox/ﬂox mice. Left, distal tubules of Ksp-Cre PKD1ﬂox/ mice. Middle, cyst epithelial cells from Ksp-Cre PKD1ﬂox/ mice; right, higher magniﬁcation of the
middle panel. Arrows show normal mitochondria, and arrowheads show mitochondria that became swollen with indistinct cristae. *, cystic cavity. (B) Electron
microscope images of proximal tubules from the kidneys of controls (/) and cysts derived from the proximal tubules of kidneys from Cy/ rats. The
mitochondria of cyst-lining cells from Cy/ kidneys were fragmented (arrow). *, cystic cavity.
Mitochondria in ADPKD Cyst Epithelial Cells Molecular and Cellular Biology
December 2017 Volume 37 Issue 24 e00337-17 mcb.asm.org 3
FIG 2 mtDNA copy number and PGC-1 expression in the kidneys of animal models of ADPKD. (A) Relative ratio of mtDNA copy number (mtDNA/nDNA) in
kidney tissue from 7-day-old Ksp-Cre PKD1ﬂox/ﬂox mice and controls (Ksp-Cre PKD1ﬂox/ mice). Top, representative kidney tissue of PAS staining. Bottom, Bar
graph showing the relative ratio of mtDNA copy number (each group, n  3). (B) Left, relative ratio of mtDNA copy number in kidney tissue from 7-week-old
Cy/ rats and 7-week-old wild-type rats (/). Upper left, representative kidney tissue after hematoxylin-eosin (HE) staining. Lower left, bar graph showing
the relative ratio of mtDNA copy number (each group, n  3). Right, relative ratio of mtDNA copy number in kidney tissue from 16-week-old Cy/ rats and
16-week-old wild-type rats (/). Upper right, representative kidney tissue after HE staining. Lower right, bar graph showing the relative ratio of mtDNA copy
number (each group, n  3). (C) Representative Western blot analysis of PGC-1 in the kidneys of 7-day-old Ksp-Cre PKD1ﬂox/ﬂox mice and controls (Ksp-Cre
PKD1ﬂox/ mice). The bar graph shows the relative ratio of protein expression calibrated by histone H1 in control kidney tissue (each group, n  3). (D)
Representative real-time PCR analysis of mRNA for PGC-1 in the kidneys of 7-day-old Ksp-Cre PKD1ﬂox/ﬂox mice and controls (each group, n  3). (E)
Representative Western blot analysis of PGC-1 in the kidneys of 7-week-old Cy/ rats and wild-type rats (/). (F) Representative real-time PCR analysis of
mRNA for PGC-1 in the kidneys of 7-week-old Cy/ rats and wild-type rats (/) (each group, n  3). The bar graph shows the relative ratio of protein
expression calibrated by histone H1 in control kidney tissue. *, P  0.05; **, P  0.01.
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mitochondria. Mitochondria from WT 9-12 were more fragmented than those from
RCTEC-DBA, as estimated by MitoTracker Red FM staining (Fig. 4D). Furthermore, assays
utilizing a mitochondrion-targeted ﬂuorescent superoxide indicator revealed signiﬁ-
cantly increased superoxide levels in WT 9-12 compared with those observed in
RCTEC-DBA (Fig. 4E), demonstrating that cyst epithelial cells produced excess super-
FIG 3 Immunohistochemical analysis of PGC-1 and 8-OHdG in the kidneys of ADPKD model animals. (A) Representative IHC staining for PGC-1 in kidney
tissue from 7-day-old Ksp-Cre PKD1ﬂox/ and Ksp-Cre PKD1ﬂox/ﬂox mice. Left, cortex of PKD1ﬂox/ mouse kidney; middle and right, lower and higher
magniﬁcations of PKD1ﬂox/ﬂox mouse kidney, respectively. The area surrounded by the dotted line in the higher-magniﬁcation image represents cyst-lining cells.
The bar graph shows the relative ratio of staining intensity of diaminobenzidine (DAB) in normal tubules and cyst-lining cells. More than 50 cells were analyzed
for staining intensity of DAB in both groups. *, representative cyst. (B) Representative IHC staining for PGC-1 in kidney tissue from 7-week-old Cy rats. Left,
IHC results for controls (/); right, IHC results for Cy/ rats. The bar graph shows the relative ratio of staining intensity of diaminobenzidine (DAB) in normal
tubules and cyst-lining cells. More than 50 cells were analyzed for staining intensity of DAB in both groups. *, representative cyst. (C) Representative IHC staining
results for 8-OHdG in kidney tissue from 7-day-old Ksp-Cre PKD1ﬂox/ﬂox mice. Left, kidney tissue from Ksp-Cre PKD1ﬂox/ mice; middle and right, kidney tissue
from Ksp-Cre PKD1ﬂox/ﬂox mice and high magniﬁcation of the black box in the middle panel, respectively. The bar graph shows the relative ratio of staining
intensity compared with that of normal tubules in Ksp-Cre PKD1ﬂox/ﬂox mice. More than 50 cells were analyzed for staining intensity of DAB in both groups. *,
representative cyst. (D) Representative IHC staining results for 8-OHdG in kidney tissue from 7-week-old Cy rats. *, representative cyst. The bar graph shows the
relative ratio of staining intensity compared with that of normal tubules in Cy rats. The 8-OHdG staining intensity was increased in cyst-lining cells compared
with normal tubular cells. More than 50 cells were analyzed for staining intensity of DAB in both groups. Results are shown as the relative ratio. Results represent
the means  standard deviations. **, P  0.01; ***, P  0.001.
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oxide owing to mitochondrial alterations. These results suggested that mitochondrial
abnormality accompanied by increased mitochondrial superoxide exists in cyst-derived
cells harboring the homozygous PKD1 mutation. Furthermore, PKD1/ mouse tubular
cells are known to exhibit decreased oxidative phosphorylation (OXPHOS) activity as
estimated by the oxygen consumption ratio (OCR) compared to normal controls
(27–29), which was conﬁrmed in the present study using an extracellular ﬂux analyzer
(Fig. 5A and B). Consistent with previous studies, except for nonmitochondrial respira-
tion, the basal respiration, ATP production, maximal respiration, spare capacity, and
proton leakage were decreased in human tubular cells with a homozygous PKD1
mutation compared with those of the control (Fig. 5C to H). These results indicated that
FIG 4 Mitochondrial abnormalities in human ADPKD cyst-derived cells with a homozygous PKD1 mutation. (A) mtDNA copy number in cyst-derived cells
containing a homozygous PKD1mutation (WT 9-12) compared to a normal tubular cell line (RCTEC-DBA) (each group, n 3). Results represent the relative ratio.
(B) Western blot analysis of PGC-1 levels in WT 9-12 and RCTEC-DBA (each group, n 3). The bar graph shows the relative ratio of protein expression calibrated
by histone H1 in normal and cyst-derived cells. (C) mRNA expression of PGC-1 in WT 9-12 and RCTEC-DBA (each group, n 3). The bar graph shows the relative
ratio of mRNA expression calibrated by GAPDH in normal and cyst-derived cells. (D) MitoTracker Red FM staining of WT 9-12 and RCTEC-DBA. Mitochondrial
elongation was evaluated using ImageJ software, and units represent the ratio of major axis to minor axis (each group, n  30). (E) Evaluation of mitochondrial
superoxide in WT 9-12 compared to RCTEC-DBA by MitoSOX Red staining (each group, n  25). The box plot shows the signal intensity. Results represent the
means  standard deviations. *, P  0.05; **, P  0.01.
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the number of mitochondria was also markedly reduced in the cells carrying the
homozygous PKD1 mutation.
Mitochondrial abnormalities in human cyst epithelial cells derived from an
ADPKD patient with a PKD1 heterozygous mutation. To identify the time at which
mitochondrial abnormality occurs in cyst-derived cells, we next used immortalized
cyst-derived cells established from a single cyst obtained from proximal cortical tubules
collected from a patient with ADPKD harboring a heterozygous PKD1mutation (WT 9-7)
(26) and a normal human renal cortical tubular epithelial cell line derived from normal
proximal tubule cells (RCTEC-Lotus tetragonolobus agglutinin [RCTEC-LTA]) to investi-
gated this issue in further detail. PKD1 mRNA expression decreased by approximately
50% in WT 9-7 compared to RCTEC-LTA (Fig. 6A). Consistent with the results for
cyst-derived cells harboring a homozygous PKD1 mutation, the mtDNA copy number
(Fig. 6B) and PGC-1 protein and mRNA expression (Fig. 6C and D) in WT 9-7 were also
lower than those observed in RCTEC-LTA, and mitochondria from WT 9-7 further
showed more fragmented shapes than those from RCTEC-LTA (Fig. 6E). As depolariza-
tion of inner mitochondrial membrane potential is also a reliable indicator of mito-
FIG 5 Alterations in mitochondrial metabolism in ADPKD-cyst-derived cells with a homozygous PKD1 mutation. (A) Measurement of the mitochondrial OCR of
normal tubular cells derived from distal tubules (RCTEC-DBA) and cyst-derived cells with a PKD1 homozygous mutation derived from distal tubules (WT 9-12).
(B) Seahorse XF Cell Mito stress test proﬁle of the key parameters of mitochondrial respiration. (C to H) Basal respiration (C), ATP production with mitochondrial
respiration (D), mitochondrial respiration and spare capacity (E and F, respectively), proton leakage from mitochondria (G), and nonmitochondrial respiration
(H) in WT 9-12 compared to RCTEC-DBA. Each group, n  30. Results represent the means  standard deviations. ***, P  0.001.
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FIG 6 Mitochondrial abnormalities in human ADPKD cyst-derived cells with a heterozygous PKD1 mutation. (A) PKD1 expression in
cyst-derived cells containing a heterozygous PKD1mutation (WT 9-7) compared to a normal tubular cell line (RCTEC-LTA) (each group, n
3). Results represent the relative ratio. (B) mtDNA copy number in WT 9-7 relative to RCTEC-LTA (each group, n  3). Results represent
the relative ratio. (C) Western blot analysis of PGC-1 levels of WT 9-7 and RCTEC-LTA (each group, n 3). The bar graph shows the relative
ratio of protein expression calibrated by histone H1 in normal and cyst-derived cells. (D) mRNA expression of PGC-1 in WT 9-7 and
RCTEC-LTA (each group, n  3). The bar graph shows the relative ratio of mRNA expression calibrated by GAPDH in normal and
cyst-derived cells. (E) MitoTracker Green staining of RCTEC-LTA and WT 9-7. Mitochondrial elongation was evaluated using ImageJ
software, and units represent the major axis to minor axis ratio (each group, n  25). (F) Evaluation of mitochondrial membrane potential.
The bar graph shows the percentage of depolarized cells, showing depolarization of inner mitochondrial membrane potential in WT 9-7
compared with that in RCTEC-LTA (each group, n  3). (G) Evaluation of intracellular ROS (superoxide). The x and y axes represent the cell
number and the ROS signaling strength, respectively, with ROS-negative cells (M1) and ROS-positive cells (M2) identiﬁed. The ROS-positive
cell number in WT 9-7 is compared with that in RCTEC-LTA. The bar graph shows the percentage of ROS-positive cells (each group, n 
3). (H) Evaluation of mitochondrial superoxide by MitoSOX Red staining. The box plot shows the signal intensity. Mitochondrial superoxide
levels in WT 9-7 are compared to those in RCTEC-LTA (each group, n  25). Results represent the means  standard deviations. **, P 
0.01; ***, P  0.001.
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chondrial dysfunction associated with increased mtROS production (30), we evaluated
the mitochondrial membrane potential and discovered increased mitochondrial depo-
larization in WT 9-7 (Fig. 6F). This alteration in mitochondrial depolarization correlated
with increased oxidative stress in cyst-derived cells, as estimated by intracellular ROS
levels, which revealed a markedly higher percentage of ROS positivity in WT 9-7 than
in RCTEC-LTA (Fig. 6G) in association with increased mitochondrial superoxide, the
primary ROS in mitochondria (Fig. 6H). Because heteroplasmic mtDNA mutations
constitute an index of increased ROS production (31), we analyzed the entire mtDNA
sequence of WT 9-7 and found accumulated heteroplasmic mtDNA mutations in WT 9-7
(Fig. 7). Some of these heteroplasmic mtDNA mutations are predicted to severely
inﬂuence each protein function and are also likely to cause mtROS production,
agreeing with a previous study reporting that moderate amounts of mtDNA het-
eroplasmy promote tumorigenesis by increasing mtROS levels (32). These results
are consistent with the previous ﬁndings suggesting that mitochondrial abnormal-
ity already existed in the cells with PKD1 heteroplasmy and persists in the cells with
PKD1 homoplasmy.
FIG 6 (Continued)
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Enhanced PKA activity and mitochondrial oxygen consumption in the cyst-
derived cells with PKD1 heteroplasmic mutation. The mitochondrial function of the
cells with PKD1 heteroplasmy was also investigated using the ﬂux analyzer (Fig. 8A).
Contrary to the results for cells with a homozygous PKD1 mutation, basal respiration
and ATP production were increased in WT 9-7 compared with RCTEC-LTA (Fig. 8B and
C). The maximal mitochondrial respiration capacity did not differ between the groups
(Fig. 8D), whereas the spare capacity of mitochondrial respiration was decreased in WT
9-7 (Fig. 8E). These results suggested that mitochondrial respiration was still maintained
in cells with a heterozygous PKD1 mutation. In comparison, a previous report showed
that although mitochondrial dysfunction suppresses baseline OXPHOS activity in cells
harboring mtDNA mutations, mitochondrial dysfunction also promotes excessive
OXPHOS activity through cAMP-PKA activation (33). This observation may explain our
results that increased basal respiration and ATP production but decreased spared
capacity occurred in the cells with the heterozygous PKD1 mutation with no difference
FIG 7 Comparison of mtDNA sequences in normal tubular cells (RCTEC-LTA) and cyst-derived cells with a heterozygous PKD1 mutation
(WT 9-7). Representative examples of mtDNA sequences, with accumulated mtDNA point mutations and heteroplasmy in cyst-derived
cells, are shown. The inﬂuence of missense mutations on protein function was analyzed using polyPhen-2. (A) The region encoding NADH
dehydrogenase subunit 4. The arrows point to mtDNA position 11204, and the arrowheads point to position 11207. A T-to-G replacement
at position 11204 translates to a phenylalanine-to-valine mutation predicted to be benign (polyPhen-2 score, 0.035). A C-to-G replacement
at position 11207 translates to a leucine-to-valine mutation predicted to be damaging (polyPhen-2 score, 0.994). (B) The region encoding
cytochrome c oxidase subunit 2. The arrows show mtDNA position 8004. Replacement of A by G at position 8004 alters the amino acid
asparagine to serine, and this mutation is predicted to be probably damaging, with a polyPhen-2 score of 0.973. (C) The region encoding
NADH dehydrogenase subunit 4. The arrows show mtDNA position 11190. Replacement of A by G at position 11190 alters the amino acid
asparagine to serine, which is predicted to be probably damaging, with a polyPhen-2 score of 0.994. (D) The region encoding NADH
dehydrogenase subunit 4. The arrows show mtDNA position 11280. Replacement of T by G at position 11280 alters the amino acid leucine
to arginine, which is predicted to be probably damaging, with a polyPhen-2 score of 0.999. (E) The region encoding NADH dehydrogenase
subunit 4. The arrows show mtDNA position 11958. Replacement of A by G at position 11958 alters the amino acid methionine to serine,
which is predicted to be benign, with a polyPhen-2 score of 0.121. (F) The region encoding cytochrome b. The arrows show mtDNA
position 15443. Replacement of C by G at position 15443 alters the amino acid leucine to valine, which is predicted to be benign, with
a polyPhen-2 score of 0.010. The black arrowhead shows mtDNA position 15447. Replacement of T by G at position 15447 alters the amino
acid leucine to proline, which is predicted to be benign, with a polyPhen-2 score of 1.000. The white arrowhead shows mtDNA position
15452. Replacement of G by A at position 15452 alters the amino acid leucine to phenylalanine, which is predicted to be benign, with
a polyPhen-2 score of 1.000.
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in maximal mitochondrial respiration, because cAMP-PKA activity likely increased in the
cells with the heterozygous PKD1mutation. Increased proton leakage (Fig. 8F) is further
suggestive of mitochondrial abnormality in the cells with the heterozygous PKD1
mutation. Notably, increased nonmitochondrial respiration was also found in the cells
with the heterozygous PKD1 mutation (Fig. 8G), as was found in the cells with the
homozygous PKD1 mutation; these data suggest that not only mitochondrial superox-
ide but also nonmitochondrial ROS will increase in cyst-derived cells compared with
normal tubular cells. To conﬁrm the effect of cAMP-PKA in mitochondrial respiration,
RCTEC-LTA and W 9-7 were treated with a PKA inhibitor (H-89), which demonstrated
that H-89 reduced basal respiration of WT 9-7 but not RCTEC-LTA (Fig. 9). Together with
the ﬁndings from the investigations in cells with a heterozygous PKD1 mutation, this
result suggests that the mitochondria of cyst-derived cells with a PKD1 heteroplasmic
mutation are not normal but exhibit cAMP-PKA-stimulated mitochondrial oxygen
consumption. This in turn will enhance superoxide production in the mitochondria of
these cells.
PKD1 affects mitochondrial functions in renal tubular cells in a dose-dependent
manner. To conﬁrm the relationship between PKD1 and mitochondrial function, we
FIG 8 Alterations in mitochondrial metabolism in ADPKD-cyst-derived cells with a heterozygous PKD1 mutation. (A) Measurement of the
mitochondrial OCR of normal tubular cells derived from proximal tubules (RCTEC-LTA) and cyst-derived cells with a PKD1 heterozygous
mutation derived from proximal tubules (WT 9-7). (B to G) Basal mitochondrial respiration and ATP production (B and C, respectively),
mitochondrial respiration (D), mitochondrial spare capacity (E), proton leakage from mitochondria (F), and nonmitochondrial respiration (G)
in WT 9-7 compared with RCTEC-LTA. Each group, n  30. Results represent the means  standard deviations. **, P  0.01; ***, P  0.001.
N.S., not signiﬁcant.
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analyzed mitochondrial functions in cells with PKD1 knockdown. Here we knocked
down PKD1 mRNA in RCTEC-LTA by using PKD1-speciﬁc small interfering RNAs (siRNAs)
(siPKD1-1 and siPKD1-2). The efﬁciency of knockdown of PKD1 was conﬁrmed with
quantitative real-time PCR (Fig. 10A). As expected, the mtDNA copy number was
decreased (Fig. 10B) and mitochondrial superoxide production was increased (Fig. 10C)
in the cells with PKD1 knockdown. In addition, the degree of PKD1 mRNA expression
correlated with mtDNA copy number and inversely correlated with mitochondrial ROS
production. Mitochondrial function was also analyzed in the cells with PKD1 knock-
down using the extracellular ﬂux analyzer (Fig. 10D), which demonstrated that all
parameters associated with mitochondria decreased according to PKD1 expression level
(Fig. 10E to I). These data indicate that PKD1 expression is very important for normal
mitochondrial function.
Signaling pathways contributing to mitochondrial abnormalities. Although
defective PKD1 expression and PGC-1 expression are expected to induce subsequent
functional and morphological alterations in mitochondria, as well as increased mito-
chondrial superoxide, in cyst epithelial cells, the signaling mechanisms associated with
reduced PGC-1 expression remain unclear. Therefore, we assessed the regulation of
PGC-1 expression and mitochondrial biogenesis by signaling pathways. The Ca2
signaling pathway is known to induce PGC-1 expression (34) via a variety of signaling
mechanisms, including adrenergic/cAMP (35), nitric oxide-soluble guanylate cyclase
(36), calcineurin (34), and p38 mitogen-activated protein kinase (MAPK), which have
previously been shown to upregulate PGC-1 expression (37). However, decreased
intracellular Ca2 has been found in MDCK cells with heterologous expression of
polycystin 1 (38), and intracellular Ca2 concentrations in WT 9-7 have not been
reported. Therefore, we conﬁrmed the presence of decreased intracellular Ca2 con-
centrations (Fig. 11A) and also increased cAMP levels (Fig. 11B), both of which are
pathogenic properties of ADPKD in cyst-derived cells. We also observed that regulators
of PGC-1 expression, including nitric oxide synthase (NOS) activity (Fig. 11C) and the
activities of the Ca2-related molecules p38 MAPK (Fig. 11D) and calcineurin (Fig. 11E),
were lower in cyst-derived cells. This relationship between a Ca2-related signaling
pathway and PGC-1 is plausible, given that ADPKD is a disease associated with Ca2
channel dysfunction.
The mitochondrion-speciﬁc antioxidant MitoQ reduces mitochondrial superox-
ide production and proliferation of cyst-derived cells. MitoQuinone (MitoQ) is a
well-characterized, mitochondrion-targeted antioxidant that accumulates near the mi-
tochondrial inner membrane to protect it from lipid peroxidation (39). To evaluate the
pathophysiological role of mitochondrial abnormalities in cyst-derived cells with a
heterozygous PKD1 mutation, we treated WT 9-7 with MitoQ and evaluated superoxide
FIG 9 OCRs of normal tubular cells (RCTEC-LTA) and cyst-derived cells with a heterozygous PKD1
mutation (WT9-7) treated with H-89 and analyzed by XF24. The OCR responses of normal tubular cells
and cyst-derived cells in response to H-89 (PKA inhibition) are shown. Each group, n  5. Results
represent the means  standard deviations. *, P  0.05; **, P  0.01. N.S., not signiﬁcant.
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FIG 10 RNA interference-mediated PKD1 knockdown and mitochondrial abnormality. Two kinds of siPKD1 (siPKD1-1 and siPKD1-2) were used. (A) PKD1
knockdown efﬁciency conﬁrmed by quantitative real-time PCR. The bar graph shows the relative ratio of PKD1 RNA expression (each group, n  3). (B)
Evaluation of mtDNA copy number by real-time PCR in association with PKD1 RNA expression levels (each group, n  3). Results represent the relative ratio.
(C) Evaluation of mitochondrial superoxide by MitoSOX Red staining as correlated with PKD1 RNA expression levels (each group, n  25). The box plot shows
(Continued on next page)
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levels. Treatment of WT 9-7 with MitoQ for 24 h reduced intracellular superoxide levels
(Fig. 12A) and ameliorated mitochondrial depolarization (Fig. 12B). In particular, we
showed that these effects were not due to p38 phosphorylation or PGC-1 expression-
mediated mechanisms: MitoQ did not affect the p38 activity or PGC-1 expression level
(Fig. 12C and D). Abnormal proliferation of cyst-lining cells is important for cyst
formation, and cyst-derived cells from ADPKD kidneys exhibit increased activity in the
ERK/MAPK pathway (40), which constitutes a key signaling cascade involved in
regulating multiple processes required for cell proliferation. Furthermore, mtROS
are important for ERK/MAPK signaling in tumor cells (41). We observed that MitoQ
treatment reduced cyst-derived cell proliferation in a dose-dependent manner and
that this effect was more signiﬁcant in WT 9-7 than in RCTEC-LTA (Fig. 12E). This
FIG 10 Legend (Continued)
the signal intensity. (D) Alterations in mitochondrial metabolism in PKD1 knockdown cells. Red, blue, and green represent negative-control siRNA, siPKD1-1, and
siPKD1-2, respectively (each group, n  20). (E to I) Basal respiration (E), ATP production with mitochondrial respiration (F), mitochondrial respiration (G), spare
capacity (H), and proton leakage from mitochondria (I) as correlated with PKD1 RNA expression levels. Results represent the means  standard deviations. *,
P  0.05; **, P  0.01; ***, P  0.001; n.s., not signiﬁcant.
FIG 11 PGC-1 regulatory mechanisms in cyst-derived cells. (A and B) Intracellular Ca2 (each group, n  8) (A) and cAMP
concentrations (each group, n  4) (B) of normal tubular cells (RCTEC-LTA) and cyst-derived cells (WT 9-7). Results represent
the relative ratio. (C and D) NOS (C) and p38 MAPK (D) activities of RCTEC-LTA and WT 9-7 (each group, n 3). Results represent
the relative ratio. The bar graph shows the relative ratio of p38 activity (phosphor-p38/p38). (E) Calcineurin activities of
RCTEC-LTA and WT 9-7 (each group, n  3). Results represent the relative ratio. All results represent the means  standard
deviations. *, P  0.05; **, P  0.01.
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FIG 12 (Continued)
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FIG 12 Amelioration of mitochondrial abnormality in cyst-derived cells by mitochondrion-targeted
therapy (MitoQ). (A) Evaluation of intracellular ROS (superoxide) to assess intracellular superoxide levels
following mitochondrion-targeted therapy using MitoQ. The x and y axes represent cell number and ROS
signaling strength, respectively, with ROS-negative cells (M1) and ROS-positive cells (M2) identiﬁed. The
ROS-positive cell number in cyst-derived cells (WT 9-7) are compared with that in control cells (RCTEC-
LTA) and MitoQ-treated (1.0 M for 48 h) cyst-derived cells (Cyst  MitoQ). The bar graph shows the
percentage of ROS-positive cells (each group, n  3). (B) Evaluation of mitochondrial membrane
potential. The bar graph shows the percentage of depolarized cells (each group, n  3). Depolarization
of inner mitochondrial membrane potential in cyst-derived cells treated with MitoQ (1.0 M for 48 h)
(MitoQ) compared with cyst-derived cells treated with vehicle (Vehicle) is shown. (C) p38 MAPK activities
in WT 9-7 treated with MitoQ (each group, n  3). Results represent the relative ratio. The bar graph
shows the relative ratio of p38 activity (phosphor-p38/p38). (D) PGC-1 expression in WT 9-7 treated with
MitoQ (each group, n  3). Results represent the relative ratio. The bar graph shows the relative ratio of
PGC-1 expression. (E) Effect of MitoQ treatment (48 h) on cell proliferation of RCTEC-LTA and WT 9-7
(each group, n  3). (F) Results of BrdU ﬂow cytometry regarding the percentages of apoptotic and
S-phase cells in control and MitoQ-treated groups (each group, n  3). (G) Western blot analysis of ERK
showing effects of MitoQ treatment on ERK activity (each group, n  3). Results represent the means 
standard deviations. *, P  0.05; **, P  0.01; ***, P  0.001. n.s., not signiﬁcant.
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inhibitory effect occurs through the mechanism of cell cycle arrest (Fig. 12F)
consequent to the inactivation of ERK-regulated cell proliferation signals (Fig. 12G)
rather than by an increase in apoptosis (Fig. 12F). These results demonstrated that
mitochondrion-derived oxidative stress likely represents an important factor for
cyst epithelial cell proliferation in ADPKD.
DISCUSSION
In this study, mitochondrial morphological changes in the kidneys of ADPKD model
animals led us to determine possible abnormalities, including disruptions in Ca2 inﬂux
and increased cAMP concentrations induced by polycystin dysfunction, which play a
central role in ADPKD pathogenesis (42). As previously reported, elevated cytosolic
Ca2-mediated PGC-1 activation is important to increase mitochondrial biogenesis
(43). Additionally, increased cAMP levels activate PKA, which enhances mitochondrial
respiration (44), whereas PKA-mediated MIC60 phosphorylation negatively regulates
the clearance of abnormal mitochondria (45). Therefore, an accumulation of mitochon-
drial abnormalities would be expected in ADPKD pathogenesis. Here, we identiﬁed that
mitochondrial abnormalities exist not only in the cells with a homozygous PKD1
mutation but also in those carrying a heterozygous PKD1 mutation. Consistent with
previous studies showing that PKD1 and PKD2 haploinsufﬁciency reduces intracellular
Ca2 levels (46, 47), this reduction of intracellular Ca2 might result in the introduction
of mitochondrial abnormalities according to the mechanisms outlined here. Notably,
owing to the lack of introns and protective histones, mtDNA is 10- to 20-fold more
vulnerable to oxidative damage and subsequently more prone to mutation than
nuclear DNA (nDNA) (48). Additionally, the frequency of mtDNA mutations is tissue
speciﬁc and markedly increased in the kidney and liver compared with that in other
human organs (49). Our data indicate that lower Ca2-related mitochondrial abnor-
mality will initiate from the stage of heterozygous mutation of the PKD1 gene. In fact,
tubular cells with heterozygous mutation of PKD1 exhibited accumulated mtDNA
mutations and increased mitochondrial superoxide compared with normal tubular
cells.
Furthermore, a recent study demonstrated the importance of PGC-1 in the patho-
genesis of kidney disease (22); in addition, PGC-1 is required for the induction of many
ROS-detoxifying enzymes (50). Together with our data, these data indicate that reduced
PGC-1 is associated with not only enhancement of mitochondrial superoxide but also
reduction of the antioxidative effect, which combined might underlie the increased
oxidative stress observed in ADPKD. Oxidative DNA damage is a major cause of DNA
mutations, with oxidative activity also being capable of inducing spontaneous mu-
tagenesis in mammalian cells (51). We propose the possibility that mitochondrial
abnormalities accumulate in tubular cells of patients with ADPKD carrying heterozy-
gous PKD1 mutations because of decreased intracellular Ca2 levels and that excessive
superoxide from abnormal mitochondria in the kidneys of patients with ADPKD causes
DNA damage, which includes second mutation of PKD-related genes. This might also
explain the high risk of development of a variety of cancers in patients with ADPKD (52),
given the necessity of DNA damage for carcinogenesis to occur. Notably, this hypoth-
esis might explain why oxidative stress is evident in patients with early-stage ADPKD,
even in those with preserved kidney function (13, 14). Furthermore, ROS also play
critical roles in regulating cell metabolism, with increased mtROS levels inducing cell
proliferation (53). As cell proliferation is an important factor in ADPKD cystogenesis,
inhibition of mitochondrial superoxide might constitute an effective strategy for the
treatment of patients with early-stage ADPKD.
A limitation of this study is that we were unable to investigate human ADPKD kidney
tissues; therefore, it could not be conﬁrmed that mitochondrial abnormality exists in
the tubular cells prior to cyst formation (before the second hit of PKD gene mutation).
Further studies are therefore needed to demonstrate this phenomenon directly in
patients.
The ﬁeld of mitochondrial biology has progressed substantially in recent years and
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has yielded numerous opportunities to translate discoveries, including MitoQ, to clinical
medicine (54). Our ﬁndings offer valuable insight into new avenues for novel thera-
peutic approaches toward ADPKD treatment, including mitochondrion-targeted ther-
apies as viable options (Fig. 13).
MATERIALS AND METHODS
ADPKD animal models. The Ksp-Cre PKD1ﬂox/ﬂox mouse was established by Shibazaki et al. as an
ADPKD model animal (15). In this model, PKD1 expression was selectively knocked out in the thick
ascending limb through the collecting duct in the kidney. Ksp-Cre PKD1ﬂox/ mice do not exhibit any
renal cysts and are used as normal controls of Ksp-Cre PKD1ﬂox/ﬂox mice. Kidney samples from 7-day-old
Ksp-Cre PKD1ﬂox/ﬂox mice (n  3), with samples from Ksp-Cre PKD1ﬂox/ mice (n  3), were kindly
provided by S. Nishio of the Hokkaido University Graduate School of Medicine (Hokkaido, Japan). The
Han:SPRD-Cy (Cy) rat strain was discovered by Kaspareit-Rittinghausen et al. (55) as a spontaneous
hereditary model that closely resembles human ADPKD. This model is characterized by a slow progres-
sion. Kidney samples of 7- and 16-week-old Han:SPRD-Cy rats were provided by S. Nagao of Fujita Health
University (Aichi, Japan). Here, we used wild-type (/) (n  3) and heterozygous (Cy/) (n  3) rats.
All protocols for animal experiments were approved by the Ethical Committee on Animal Experiments of
the University of Tokyo (M-P16-082), and all animal experiments were conducted in accordance with
institutional guidelines.
Cell culture. Loghman-Adham et al. (56) developed immortalized cells from the cyst epithelia of
individual cysts from human patients with ADPKD and a control cell line from normal human renal cortex.
PKD1 mutation-containing immortalized cyst-derived cells WT9-7 (CRL-2830; American Type Culture
Collection, Manassas, VA) and WT 9-12 (CRL-2833; American Type Culture Collection) were used as cyst
epithelial cells. WT 9-7 is of cyst proximal tubule origin, and WT 9-12 is of cyst distal tubule origin. The
heterozygous PKD1 mutation in WT 9-7 and homozygous PKD1 mutation in WT 9-12 were reported by
Nauli et al. (26). Immortalized normal human RCTECs derived from proximal tubules (RCTEC-Lotus
tetragonolobus agglutinin [RCTEC-LTA]) and distal tubules (RCTEC-Dolichos biﬂorus agglutin [RCTEC-DBA])
(56) were used for in vitro studies as normal controls. Both cell lines were grown at 37°C in 95% air–5%
CO2 in Dulbecco’s modiﬁed Eagle’s medium (DMEM) (D6429; Sigma-Aldrich, St. Louis, MO) supplemented
with 10% fetal bovine serum (Sigma-Aldrich) in ﬂasks.
DNA isolation and mtDNA copy number analysis. Assessment of human and rat mtDNA copy
numbers by quantitative real-time PCR was performed as previously described (57). Total DNA was
isolated from whole kidneys and normal and cystic tubular cells using a NucleoSpin tissue kit (TaKaRa Bio,
Otsu, Japan). DNA (10 ng) was subjected to quantitative real-time PCR on a CFX96 system (Bio-Rad,
Hercules, CA) with Kapa SYBR fast universal 2 quantitative PCR (qPCR) master mix (Kapa Biosystems,
Wilmington, MA). The PCR protocol consisted of 95°C for 30 s followed by 40 cycles of 95°C for 5 s,
annealing at 60°C for 30 s, and a 72°C extension for 10 s. Human and rat mtDNA copy numbers and nDNA
content were determined by amplifying a short region of the MT-TL1 (tRNA-LeuUUR) and B2M genes (58),
respectively, whereas those in rats were assessed by amplifying Mt-cyb and Actb, respectively (59). The
mtDNA copy number was then calculated according to the mtDNA/nDNA ratio. All primers are listed in
Table 1.
FIG 13 Schematic of the pathway proposed in this study. A decreased intracellular Ca2 concentration
reduces PGC-1 expression via calcineurin, p38 MAPK, and NOS deactivation, whereas PKA upregulates
mitochondrial respiration. These mechanisms enhance mitochondrial superoxide production, which
contributes to ERK/MAPK signaling in cyst epithelial cells. PC 1, polycystin 1; PC 2, polycystin 2; AC 6,
adenylate cyclase 6; V2R, vasopressin-2 receptor; Gs, stimulatory G protein.
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mRNA extraction and expression analysis. mRNAs were isolated with RNAiso Plus (TaKaRa Bio).
Reverse transcription was performed using PrimeScript RT master mix (TaKaRa Bio). Primer pairs designed
to generate overlapping PGC-1 (PPARGC1A), PKD1, and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) fragments are listed in Table 2. We used 10 ng of mtDNA for quantitative real-time PCR using
Kapa SYBR fast universal 2 qPCR master mix (Kapa Biosystems) run on a CFX96 system (Bio-Rad). The
PCR protocol consisted of 95°C for 30 s followed by 40 cycles at 95°C for 5 s, annealing at 62°C for 30 s,
and a 72°C extension for 5 s, accompanied by real-time data collection. The relative ratios of mRNA of
PGC-1 and PKD1 expression were calibrated by GAPDH.
Antibodies. Mouse monoclonal anti-GAPDH antibody (sc-32233), rabbit polyclonal anti-ERK1
antibody sc-94), mouse monoclonal anti-pERK antibody (sc-7383), and mouse monoclonal anti-
histone H1 antibody (sc-8030) were purchased from Santa Cruz Biotechnology (Dallas, TX) and used
for Western blot (WB) analysis. Anti-PGC-1 antibody (ab54481) was obtained from Abcam (Cam-
bridge, UK) and used for WB and IHC analyses. Anti-8-OHdG antibody (MOG-020P) was obtained
from the Japan Institute for the Control of Aging (Shizuoka, Japan). Rabbit polyclonal anti-p38 MAPK
antibody and rabbit polyclonal anti-phospho-p38 MAPK were obtained from Cell Signaling Tech-
nology, Japan (Tokyo, Japan). Horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (170-
6515; Bio-Rad) and HRP-conjugated donkey anti-goat IgG (sc-2020; Santa Cruz Biotechnology) were
used as secondary antibodies for WB analysis.
WB analysis. Nuclear extracts from cultured cells or animal kidney tissue were obtained using an
NE-PER nuclear and cytoplasmic extraction kit (Thermo Fisher Scientiﬁc, Waltham, MA), and the
protein concentration was measured using a Pierce bicinchoninic acid (BCA) protein assay kit
(Thermo Fisher Scientiﬁc). For other Western blot (WB) analyses, whole-cell lysates of cultured cells
or animal kidney tissue were obtained using a nuclear extract kit (Active Motif, Carlsbad, CA). Sodium
dodecyl sulfate (SDS) sample buffer containing 0.70 M Tris-HCl (pH 6.8), 20% SDS, 72% glycerol, 10%
-mercaptoethanol, and 0.024% bromophenol blue was added to the lysate and then separated on
10% SDS-polyacrylamide gels. After electrophoresis, proteins were transferred to polyvinylidene
diﬂuoride membranes (GE Healthcare, Little Chalfont, UK) in a Tris-glycine transfer buffer (48 mM Tris
buffer, 39 mM glycine, 0.05% SDS, and 10% methanol). Membranes were incubated with primary and
secondary antibodies, and an ECL Plus Western blot system (GE Healthcare) was used to detect
immunoreactive bands. Experiments were repeated three times, and representative data are pre-
sented in the ﬁgures. Band intensities were quantiﬁed using ImageJ software (National Institutes of
Health, Bethesda, MD).
Kidney IHC. For immunohistochemistry (IHC), kidneys were ﬁxed in Mildform 10N (Wako Pure
Chemical Industries, Saitama, Japan) for 8-OHdG and 4-hydroxy-2-nonenal (4-HNE) staining and in
methacarn (60% methanol, 30% chloroform, and 10% acetic acid) for PGC-1 staining after embedding
in parafﬁn. Sections of 3-m thickness were incubated with the appropriate primary antibody and a
Vectastain Elite ABC HRP kit (Vector Laboratories, Burlingame, CA) and developed by incubation with
ImmPACT diaminobenzidine (DAB) peroxidase substrate (Vector Laboratories). Signal intensity was
quantiﬁed using a Mantra quantitative pathology workstation with inForm image analysis software
(PerkinElmer Japan, Yokohama, Japan). This software can recognize the cells with nuclear staining
TABLE 1 Primers for analysis of mtDNA copy number
Species Genome Target
Primer sequence, 5=¡3=
Forward Reverse
Rattus norvegicus Mitochondrial Cytochrome b GCAGCTTAACATTCCGCCCAATCA TACTGGTTGGCCTCCGATTCATGT
Nuclear Actin ATCATGTTTGAGACCTTCAACACCC CATCTCTTGCTCGAAGTCTAGG
Mus musculus Mitochondrial tRNA-Val CTAGAAACCCCGAAACCAAA CCAGCTATCACCAAGCTCGT
Nuclear 2-Microglobulin ATGGGAAGCCGAACATACTG CAGTCTCAGTGGGGGTGAAT
Homo sapiens Mitochondrial tRNA-Leu CACCCAAGAACAGGGTTTGT TGGCCATGGGTATGTTGTTA
Nuclear 2-Microglobulin TGCTGTCTCCATGTTTGATGTATCT TCTCTGCTCCCCACCTCCAAGT
TABLE 2 Primers for analysis of PGC-1 RNA expression
Species Target
Primer sequence, 5=¡3=
Forward Reverse
Rattus norvegicus GAPDH CAACTCCCTCAAGATTGTCAGCAAGGCAT GGCATGGACTGTGGTCATGA
PGC-1 GAAAAAGCTTGACTGGCGTC GCAGCACACTCTATGTCACTC
Mus musculus GAPDH CATGGCCTTCCGTGTTCCTA CCTGCTTCACCACCTTCTTGAT
PGC-1 GAAAAAGCTTGACTGGCGTC GCAGCACACTCTATGTCACTC
Homo sapiens GAPDH CCTCAACGACCACTTTGTCA TTACTCCTTGGAGGCCATGT
PGC-1 GACACCCTCTTCTCTTCCTTCTTT CGGCTGTTACTCTCTCTCCTTG
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automatically and calculate the signal intensity of DAB staining per cell. Over 50 normal tubular and cyst
epithelial cells were quantiﬁed with respect to signal intensity.
Mitochondrial morphology and superoxide quantiﬁcation. To analyze mitochondrial morphol-
ogy, WT 9-7 and RCTEC-LTA cells were stained with MitoTracker Green FM (M7514; Life Technologies,
Grand Island, NY), and WT 9-12 and RCTEC-DBA cells were stained with MitoTracker Red FM (M22425; Life
Technologies). Brieﬂy, 1 mM stock solutions of MitoTracker solutions were diluted with DMEM to a 50 nM
working concentration and incubated with cells for 15 min under growth conditions. A BZ-9000
ﬂuorescence microscope (Keyence, Osaka, Japan) was used for observation. Automated quantiﬁca-
tion of mitochondrial morphology was done using ImageJ software. The mean area/perimeter ratio
was employed as an index of mitochondrial interconnectivity, with inverse circularity used as a
measurement of mitochondrial elongation and validated using well-characterized mediators of
mitochondrial ﬁssion and fusion. Increased ﬂuorescence of MitoSOX Red (M-36008; Molecular
Probes, Eugene, OR) was used as an assay for mitochondrial superoxide production as previously
described (60). Cells were incubated with 2.5 M MitoSOX Red for 10 min in the dark at 37°C and
then rinsed three times with phosphate-buffered saline prior to ﬂuorescence measurement using a
BZ-9000 ﬂuorescence microscope (Keyence). The ﬂuorescence intensity of each randomly selected
cell was quantiﬁed using ImageJ software as previously described (61). Results are expressed as
compiled means  standard deviations from at least three independent experiments, representing
relative ﬂuorescence intensity normalized to controls.
Cell analysis. Oxidative stress, mitochondrial membrane potential, and cell counts were evaluated
using a Muse oxidative stress kit, MitoPotential kit, and count and viability kit, respectively, on a Muse cell
analyzer (Merck Millipore, Billerica, MA), and assays were performed according to the manufacturer’s
instructions. The Muse oxidative stress kit provides the relative percentages of ROS-negative and
-positive cells, based on the intracellular detection of superoxide radicals and using an oxidative stress
reagent based on dihydroethidium. The MitoPotential assay utilizes MitoPotential dye, a cationic,
lipophilic dye that detects changes in mitochondrial membrane potential, with 7-aminoactinomycin D
(7-ADD) used as an indicator of cell death.
mtDNA sequence analysis. mtDNA was isolated from cultured cells using a mitochondrion
isolation kit (Pierce Biotechnology, Rockford, IL) and a NucleoSpin tissue kit (TaKaRa Bio). Primer
pairs designed to generate overlapping mtDNA fragments are listed in Table 3. We used 10 ng of
mtDNA for quantitative real-time PCR using Kapa SYBR fast universal 2 qPCR master mix (Kapa
Biosystems) run on a CFX96 system (Bio-Rad). The PCR protocol consisted of 95°C for 30 s followed
by 40 cycles at 95°C for 5 s, annealing at 59°C for 30 s, and a 72°C extension for 3 min, accompanied
by real-time data collection. PCR products were sequenced by Euroﬁns Genomics (Tokyo, Japan), and
mtDNA sequences were identiﬁed.
siRNA-mediated depletion of PKD1 expression. We used Hs_PKD1_2 (SI00006454, termed
siPKD1-1) and Hs_PKD1_6 (SI03115560, termed siPKD1-2) as human PKD1-speciﬁc siRNAs. We used
AllStar Neg siRNA AF 488 as the negative control of siRNA. These siRNAs were obtained from Qiagen
TABLE 3 Primers for analysis of mtDNA sequence
Mitochondrial
DNA fragment
(nucleotide positions)
Primer sequence, 5=¡3=
Forward Reverse
1 (47–1704) GCATTTGGTATTTTCGTCTGGGG AGTAAGGTGGAGTGGGTTTGG
2 (755–1914) GCATCAAGCACGCAGCAAT CTGGTTTCGGGGGTCTTAGC
3 (1616–3182) ACACAAAGCACCCAACTTACAC TATCATTTACGGGGGAAGGCG
4 (2414–3564) CCTCACTGTCAACCCAACAC TCATAGTAGAAGAGCGATGGTG
5 (3125–5491) ACGAAAGGACAAGAGAAATAAGGC GGGGAGATAGGTAGGAGTAGCG
6 (3878–5468) CAGAGACCAACCGAACCCC GGTAAGGGCGATGAGTGTGG
7 (4950–7140) TCCATCATAGCAGGCAGTTGAG GGATTTTGGCGTAGGTTTGGTC
8 (6048–7380) GGTAACGACCACATCTACAACG CCAGGTTTATGGAGGGTTCTTC
9 (6416–7288) AAAACCCCCTGCCATAACCC AGAGAAATGAATGAGCCTACAGATG
10 (6959–8947) CCTGACTGGCATTGTATTAGCA GTATGGGGATAAGGGGTGTAGG
11 (7772–8939) ACCGTCTGAACTATCCTGCC ATAAGGGGTGTAGGTGTGCC
12 (8538–10147) TCTGTTCGCTTCATTCATTGCC TAGCCGTTGAGTTGTGGTAGTC
13 (9273–9792) TCAGCCCTCCTAATGACCTCC TTGAGCCGTAGATGCCGTC
14 (9499–11209) TCTGAGCCTTTTACCACTCCAG TAGGAAGTATGTGCCTGCGTTC
15 (10291–11166) CCCTACAAACAACTAACCTGCC ATCGGGTGATGATAGCCAAGG
16 (10830–12623) GAATCAACACAACCACCCACAG ACGAACAATGCTACAGGGATGA
17 (11597–12407) ACAGACCTAAAATCGCTCATTGC ACGAGGGTGGTAAGGATGGG
18 (11989–13568) ATTTACCACAACACAATGGGGC ATAGATAGGGCTCAGGCGTTTG
19 (12801–13778) CAGTTGATGATACGCCCGAG TTGTTTGGAAGGGGGATGCG
20 (13436–14765) CTCTCACTTCAACCTCCCTCAC TTTTGCGTATTGGGGTCATTGG
21 (13926–15454) TAGCATCACACACCGCACAATC AAGGAAGAGAAGTAAGCCGAGG
22 (14684–15633) CGGACTACAACCACGACCAA AGTAATAGGGCAAGGACGCC
23 (15264–16509) CCACCCTCACACGATTCTTTAC AGGAACCAGATGTCGGATACAG
24 (15977–16521) CCACCATTAGCACCCAAAGC TGACCCTGAAGTAGGAACCAGA
25 (16245–382) CAACTCCAAAGCCACCCCTC GGCTGGTGTTAGGGTTCTTTG
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(Venlo, The Netherlands). Cells were transfected with siRNAs by using Lipofectamine RNAiMAX
transfection reagent obtained from Invitrogen (Carlsbad, CA) and analyzed at 48 h after transfection.
Knockdown efﬁciency was conﬁrmed by quantitative real-time PCR by using speciﬁc primers as listed
in Table 4.
Intracellular Ca2 concentration. Cells were incubated with 2.5 M Fura-2 AM (F015; Dojindo,
Kumamoto, Japan) diluted with recording medium (20 mmol/liter HEPES, 115 mmol NaCl, 5.4 mmol/liter
KCl, 0.8 mmol/liter MgCl2, 1.8 mmol/liter CaCl2, and 13.8 mmol/liter glucose [pH 7.4]) with 0.05% pluronic
F-127 (P2443; Sigma-Aldrich) for 1 h at 37°C in 95% air–5% CO2. Fura 2-AM was excited at 340 nm and
380 nm, and emission at 510 nm was recorded using a 2300 EnSpire (PerkinElmer Japan). Data represent
the results of three independent experiments performed in duplicate.
Intracellular cAMP assay. The cAMP concentration was measured using the enzyme immuno-
assay Parameter kit (KGE002B; R&D Systems, Minneapolis, MN) according to the manufacturer’s
instructions. Extracellular cAMP was not measured, and no correction was applied for cAMP released from
cells. Absorbance values were measured using a 2300 EnSpire (PerkinElmer Japan) and converted to cAMP
concentrations according to the manufacturer’s instructions. Data represent the results of two independent
experiments performed in duplicate, and all values were normalized to the values from controls.
Calcineurin assay. Cell lysates were prepared using reagents provided in the calcineurin cellular
activity assay kit (BML-AK816; Enzo Life Science, Farmingdale, NY), and the assay was performed
according to the manufacturer’s instructions. Absorbance values were measured using a 2300 EnSpire
and converted into the amount of PO4 released by calcineurin according to the manufacturer’s instruc-
tions. All values were normalized to control values.
NOS activity assay. Intracellular NOS activity was measured using a nitrate/nitrite colorimetric assay
kit (760871; Cayman Chemical, Ann Arbor, MI) according to the manufacturer’s instructions. Absorbance
values were measured using a 2300 EnSpire and converted into the amounts of nitrate and nitrite
according to the manufacturer’s instructions.
BrdU ﬂow cytometry. Cells were analyzed by staining with bromodeoxyuridine (BrdU) and 7-ADD
(BrdU ﬂow kit; BD Pharmingen, Franklin Lakes, NJ) according to the manufacturer’s instructions. The
experiment was performed in triplicate, and samples were analyzed by ﬂow cytometry (BD FACSVerse;
BD Pharmingen).
OCR. An XF96 extracellular ﬂux analyzer (Agilent Technologies, Santa Clara, CA) was used to
determine intracellular bioenergetic proﬁles. The cell number seeded onto each well of an XF96 cell
culture microplate was 1.0  104 cells/well. The oxygen consumption ratio (OCR) was assessed in
glucose-containing XF base medium (25 mM glucose, 2 mM pyruvate glutamine, and 1 mM pyruvate)
according to the manufacturer’s instructions. The concentrations of oligomycin, carbonyl cyanide-4-
(triﬂuoromethoxy)phenylhydrazone (FCCP), and antimycin A/rotenone were 1, 0.5, and 1 M, respec-
tively. XF24 was also used to determine the OCR in cells treated with H-89. The cell number seeded onto
each well of an XF24 cell culture microplate was 2.5  104 cells/well.
Chemical reagents. MitoQuinone {phosphonium [10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-
cyclohexadien-1-yl)decyl] triphenyl-mesylate} (MitoQ) was ﬁrst designed as an antioxidant intended
to block mitochondrial oxidative damage by preventing lipid peroxidation (62). MitoQ was kindly
provided by M. Murphy (MRC Mitochondrial Biology Unit, Cambridge, UK).
Statistical analysis. All data are presented as means  standard deviations. Data for two groups
were analyzed by the unpaired t test, and those for more than two groups were compared by analysis
of variance with a Tukey-Kramer test. A P value of 0.05 was considered statistically signiﬁcant. JMP Pro
software version 12.2.0 (SAS Institute Japan, Tokyo, Japan) was used for data analysis.
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TABLE 4 Primers for analysis of human PKD1 knockdown efﬁciency
Target
Primer sequence, 5=¡3=
Forward Reverse
siPKD1-1 CTCAATGCCTCCAACGCAGT CAGCCAGCAGGATCTGAAAATG
siPKD1-2 GCTTCACTAGCTTCGACCAGG TCGGCATAATGTCTTGCCAAAG
GAPDH CCTCAACGACCACTTTGTCA TTACTCCTTGGAGGCCATGT
Mitochondria in ADPKD Cyst Epithelial Cells Molecular and Cellular Biology
December 2017 Volume 37 Issue 24 e00337-17 mcb.asm.org 21
REFERENCES
1. Harris PC. 2002. Molecular basis of polycystic kidney disease: PKD1, PKD2
and PKHD1. Curr Opin Nephrol Hypertens 11:309–314. https://doi.org/
10.1097/00041552-200205000-00007.
2. Chapman AB, Devuyst O, Eckardt KU, Gansevoort RT, Harris T, Horie S,
Kasiske BL, Odland D, Pei Y, Perrone RD, Pirson Y, Schrier RW, Torra R, Torres
VE, Watnick T, Wheeler DC, Conference Participants. 2015. Autosomal-
dominant polycystic kidney disease (ADPKD): executive summary from a
Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Confer-
ence. Kidney Int 88:17–27. https://doi.org/10.1038/ki.2015.59.
3. Hateboer N, van Dijk MA, Bogdanova N, Coto E, Saggar-Malik AK, San
Millan JL, Torra R, Breuning M, Ravine D. 1999. Comparison of pheno-
types of polycystic kidney disease types 1 and 2. European PKD1-PKD2
Study Group. Lancet 353:103–107.
4. Heggö O. 1966. A microdissection study of cystic disease of the kidneys
in adults. J Pathol Bacteriol 91:311–315. https://doi.org/10.1002/path
.1700910204.
5. Baert L. 1978. Hereditary polycystic kidney disease (adult form): a mi-
crodissection study of two cases at an early stage of the disease. Kidney
Int 13:519–525. https://doi.org/10.1038/ki.1978.75.
6. Piontek K, Menezes LF, Garcia-Gonzalez MA, Huso DL, Germino GG. 2007.
A critical developmental switch deﬁnes the kinetics of kidney cyst
formation after loss of Pkd1. Nat Med 13:1490–1495. https://doi.org/10
.1038/nm1675.
7. Piazzon N, Maisonneuve C, Guilleret I, Rotman S, Constam DB. 2012.
Bicc1 links the regulation of cAMP signaling in polycystic kidneys to
microRNA-induced gene silencing. J Mol Cell Biol 4:398–408.
8. Yamaguchi T, Pelling JC, Ramaswamy NT, Eppler JW, Wallace DP, Nagao
S, Rome LA, Sullivan LP, Grantham JJ. 2000. cAMP stimulates the in vitro
proliferation of renal cyst epithelial cells by activating the extracellular
signal-regulated kinase pathway. Kidney Int 57:1460–1471. https://doi
.org/10.1046/j.1523-1755.2000.00991.x.
9. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Hi-
gashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS, TOMPO 3 4
Trial Investigators. 2012. Tolvaptan in patients with autosomal dominant
polycystic kidney disease. N Engl J Med 367:2407–2418. https://doi.org/
10.1056/NEJMoa1205511.
10. Luciano RL, Dahl NK. 2014. Extra-renal manifestations of autosomal
dominant polycystic kidney disease (ADPKD): considerations for routine
screening and management. Nephrol Dial Transplant 29:247–254.
https://doi.org/10.1093/ndt/gft437.
11. Qian F, Watnick TJ, Onuchic LF, Germino GG. 1996. The molecular basis
of focal cyst formation in human autosomal dominant polycystic kidney
disease type I. Cell 87:979–987. https://doi.org/10.1016/S0092-8674
(00)81793-6.
12. Brasier JL, Henske EP. 1997. Loss of the polycystic kidney disease (PKD1)
region of chromosome 16p13 in renal cyst cells supports a loss-of-
function model for cyst pathogenesis. J Clin Invest 99:194–199. https://
doi.org/10.1172/JCI119147.
13. Klawitter J, Reed-Gitomer BY, McFann K, Pennington A, Abebe KZ,
Klepacki J, Cadnapaphornchai MA, Brosnahan G, Chonchol M, Christians
U, Schrier RW. 2014. Endothelial dysfunction and oxidative stress in
polycystic kidney disease. Am J Physiol Renal Physiol 307:F1198–F1206.
https://doi.org/10.1152/ajprenal.00327.2014.
14. Menon V, Rudym D, Chandra P, Miskulin D, Perrone R, Sarnak M. 2011.
Inﬂammation, oxidative stress, and insulin resistance in polycystic kidney
disease. Clin J Am Soc Nephrol 6:7–13. https://doi.org/10.2215/CJN
.04140510.
15. Shibazaki S, Yu Z, Nishio S, Tian X, Thomson RB, Mitobe M, Louvi A,
Velazquez H, Ishibe S, Cantley LG, Igarashi P, Somlo S. 2008. Cyst
formation and activation of the extracellular regulated kinase pathway
after kidney speciﬁc inactivation of Pkd1. Hum Mol Genet 17:1505–1516.
https://doi.org/10.1093/hmg/ddn039.
16. Nagao S, Kugita M, Yoshihara D, Yamaguchi T. 2012. Animal models for
human polycystic kidney disease. Exp Anim 61:477–488. https://doi.org/
10.1538/expanim.61.477.
17. Detmer SA, Chan DC. 2007. Functions and dysfunctions of mitochondrial
dynamics. Nat Rev Mol Cell Biol 8:870–879. https://doi.org/10.1038/
nrm2275.
18. Chen H, Vermulst M, Wang YE, Chomyn A, Prolla TA, McCaffery JM, Chan
DC. 2010. Mitochondrial fusion is required for mtDNA stability in skeletal
muscle and tolerance of mtDNA mutations. Cell 141:280–289. https://
doi.org/10.1016/j.cell.2010.02.026.
19. Baumann K. 2010. Organelle dynamics: fusing for stability. Nat Rev Mol
Cell Biol 11:391. https://doi.org/10.1038/nrm2910.
20. Cho YM, Park KS, Lee HK. 2007. Genetic factors related to mitochondrial
function and risk of diabetes mellitus. Diabetes Res Clin Pract 77(Suppl
1):S172–S177. https://doi.org/10.1016/j.diabres.2007.01.052.
21. Hood DA. 2009. Mechanisms of exercise-induced mitochondrial biogen-
esis in skeletal muscle. Appl Physiol Nutr Metab 34:465–472. https://doi
.org/10.1139/H09-045.
22. Tran MT, Zsengeller ZK, Berg AH, Khankin EV, Bhasin MK, Kim W, Clish CB,
Stillman IE, Karumanchi SA, Rhee EP, Parikh SM. 2016. PGC1 drives NAD
biosynthesis linking oxidative metabolism to renal protection. Nature
531:528–532. https://doi.org/10.1038/nature17184.
23. Wang CH, Wu SB, Wu YT, Wei YH. 2013. Oxidative stress response
elicited by mitochondrial dysfunction: implication in the pathophys-
iology of aging. Exp Biol Med 238:450–460. https://doi.org/10.1177/
1535370213493069.
24. Murphy MP. 2009. How mitochondria produce reactive oxygen species.
Biochem J 417:1–13. https://doi.org/10.1042/BJ20081386.
25. Dromparis P, Michelakis ED. 2013. Mitochondria in vascular health and
disease. Annu Rev Physiol 75:95–126. https://doi.org/10.1146/annurev
-physiol-030212-183804.
26. Nauli SM, Rossetti S, Kolb RJ, Alenghat FJ, Consugar MB, Harris PC, Ingber
DE, Loghman-Adham M, Zhou J. 2006. Loss of polycystin-1 in human
cyst-lining epithelia leads to ciliary dysfunction. J Am Soc Nephrol
17:1015–1025. https://doi.org/10.1681/ASN.2005080830.
27. Hajarnis S, Lakhia R, Yheskel M, Williams D, Sorourian M, Liu X, Abou-
dehen K, Zhang S, Kersjes K, Galasso R, Li J, Kaimal V, Lockton S, Davis S,
Flaten A, Johnson JA, Holland WL, Kusminski CM, Scherer PE, Harris PC,
Trudel M, Wallace DP, Igarashi P, Lee EC, Androsavich JR, Patel V. 2017.
microRNA-17 family promotes polycystic kidney disease progression
through modulation of mitochondrial metabolism. Nat Commun
8:14395. https://doi.org/10.1038/ncomms14395.
28. Padovano V, Kuo IY, Stavola LK, Aerni HR, Flaherty BJ, Chapin HC, Ma M,
Somlo S, Boletta A, Ehrlich BE, Rinehart J, Caplan MJ. 2017. The polycys-
tins are modulated by cellular oxygen-sensing pathways and regulate
mitochondrial function. Mol Biol Cell 28:261–269. https://doi.org/10
.1091/mbc.E16-08-0597.
29. Menezes LF, Lin CC, Zhou F, Germino GG. 2016. Fatty acid oxidation is
impaired in an orthologous mouse model of autosomal dominant poly-
cystic kidney disease. EBioMedicine 5:183–192. https://doi.org/10.1016/
j.ebiom.2016.01.027.
30. Zorov DB, Filburn CR, Klotz LO, Zweier JL, Sollott SJ. 2000. Reactive
oxygen species (ROS)-induced ROS release: a new phenomenon accom-
panying induction of the mitochondrial permeability transition in car-
diac myocytes. J Exp Med 192:1001–1014. https://doi.org/10.1084/jem
.192.7.1001.
31. Park JS, Sharma LK, Li H, Xiang R, Holstein D, Wu J, Lechleiter J, Naylor
SL, Deng JJ, Lu J, Bai Y. 2009. A heteroplasmic, not homoplasmic,
mitochondrial DNA mutation promotes tumorigenesis via alteration in
reactive oxygen species generation and apoptosis. Hum Mol Genet
18:1578–1589. https://doi.org/10.1093/hmg/ddp069.
32. Sullivan LB, Chandel NS. 2014. Mitochondrial reactive oxygen species
and cancer. Cancer Metab 2:17. https://doi.org/10.1186/2049-3002-2-17.
33. Acin-Perez R, Salazar E, Brosel S, Yang H, Schon EA, Manfredi G. 2009.
Modulation of mitochondrial protein phosphorylation by soluble adeny-
lyl cyclase ameliorates cytochrome oxidase defects. EMBO Mol Med
1:392–406. https://doi.org/10.1002/emmm.200900046.
34. Handschin C, Rhee J, Lin J, Tarr PT, Spiegelman BM. 2003. An autoreg-
ulatory loop controls peroxisome proliferator-activated receptor gamma
coactivator 1alpha expression in muscle. Proc Natl Acad Sci U S A
100:7111–7116. https://doi.org/10.1073/pnas.1232352100.
35. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM.
1998. A cold-inducible coactivator of nuclear receptors linked to
adaptive thermogenesis. Cell 92:829–839. https://doi.org/10.1016/
S0092-8674(00)81410-5.
36. Nisoli E, Clementi E, Paolucci C, Cozzi V, Tonello C, Sciorati C, Bracale R,
Valerio A, Francolini M, Moncada S, Carruba MO. 2003. Mitochondrial
biogenesis in mammals: the role of endogenous nitric oxide. Science
299:896–899. https://doi.org/10.1126/science.1079368.
Ishimoto et al. Molecular and Cellular Biology
December 2017 Volume 37 Issue 24 e00337-17 mcb.asm.org 22
37. Rasbach KA, Schnellmann RG. 2007. Signaling of mitochondrial biogen-
esis following oxidant injury. J Biol Chem 282:2355–2362. https://doi
.org/10.1074/jbc.M608009200.
38. Weber KH, Lee EK, Basavanna U, Lindley S, Ziegelstein RC, Germino GG,
Sutters M. 2008. Heterologous expression of polycystin-1 inhibits endo-
plasmic reticulum calcium leak in stably transfected MDCK cells. Am J
Physiol Renal Physiol 294:F1279–1286. https://doi.org/10.1152/ajprenal
.00348.2007.
39. Smith RA, Murphy MP. 2010. Animal and human studies with the
mitochondria-targeted antioxidant MitoQ. Ann N Y Acad Sci 1201:
96–103. https://doi.org/10.1111/j.1749-6632.2010.05627.x.
40. Nagao S, Yamaguchi T, Kusaka M, Maser RL, Takahashi H, Cowley BD,
Grantham JJ. 2003. Renal activation of extracellular signal-regulated
kinase in rats with autosomal-dominant polycystic kidney disease. Kid-
ney Int 63:427–437. https://doi.org/10.1046/j.1523-1755.2003.00755.x.
41. Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M,
Kalyanaraman B, Mutlu GM, Budinger GR, Chandel NS. 2010. Mitochon-
drial metabolism and ROS generation are essential for Kras-mediated
tumorigenicity. Proc Natl Acad Sci U S A 107:8788–8793. https://doi.org/
10.1073/pnas.1003428107.
42. Calvet JP. 2015. The role of calcium and cyclic AMP in PKD, p 169–196.
In Li X (ed), Polycystic kidney disease. Codon Publications, Brisbane,
Australia.
43. Ojuka EO, Jones TE, Han DH, Chen M, Holloszy JO. 2003. Raising Ca2 in
L6 myotubes mimics effects of exercise on mitochondrial biogenesis in
muscle. FASEB J 17:675–681. https://doi.org/10.1096/fj.02-0951com.
44. Acin-Perez R, Gatti DL, Bai Y, Manfredi G. 2011. Protein phosphorylation
and prevention of cytochrome oxidase inhibition by ATP: coupled mech-
anisms of energy metabolism regulation. Cell Metab 13:712–719. https://
doi.org/10.1016/j.cmet.2011.03.024.
45. Akabane S, Uno M, Tani N, Shimazaki S, Ebara N, Kato H, Kosako H, Oka
T. 2016. PKA regulates PINK1 stability and Parkin recruitment to dam-
aged mitochondria through phosphorylation of MIC60. Mol Cell 62:
371–384. https://doi.org/10.1016/j.molcel.2016.03.037.
46. Ahrabi AK, Jouret F, Marbaix E, Delporte C, Horie S, Mulroy S, Boulter C,
Sandford R, Devuyst O. 2010. Glomerular and proximal tubule cysts as
early manifestations of Pkd1 deletion. Nephrol Dial Transplant 25:
1067–1078. https://doi.org/10.1093/ndt/gfp611.
47. Qian Q, Hunter LW, Li M, Marin-Padilla M, Prakash YS, Somlo S, Harris PC,
Torres VE, Sieck GC. 2003. Pkd2 haploinsufﬁciency alters intracellular
calcium regulation in vascular smooth muscle cells. Hum Mol Genet
12:1875–1880. https://doi.org/10.1093/hmg/ddg190.
48. Richter C, Park JW, Ames BN. 1988. Normal oxidative damage to mito-
chondrial and nuclear DNA is extensive. Proc Natl Acad Sci U S A
85:6465–6467. https://doi.org/10.1073/pnas.85.17.6465.
49. Samuels DC, Li C, Li B, Song Z, Torstenson E, Boyd Clay H, Rokas A,
Thornton-Wells TA, Moore JH, Hughes TM, Hoffman RD, Haines JL,
Murdock DG, Mortlock DP, Williams SM. 2013. Recurrent tissue-speciﬁc
mtDNA mutations are common in humans. PLoS Genet 9:e1003929.
https://doi.org/10.1371/journal.pgen.1003929.
50. St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jäger S, Handschin C,
Zheng K, Lin J, Yang W, Simon DK, Bachoo R, Spiegelman BM. 2006.
Suppression of reactive oxygen species and neurodegeneration by the
PGC-1 transcriptional coactivators. Cell 127:397–408. https://doi.org/10
.1016/j.cell.2006.09.024.
51. Rossman TG, Goncharova EI. 1998. Spontaneous mutagenesis in mam-
malian cells is caused mainly by oxidative events and can be blocked by
antioxidants and metallothionein. Mutat Res 402:103–110. https://doi
.org/10.1016/S0027-5107(97)00287-X.
52. Yu TM, Chuang YW, Yu MC, Chen CH, Yang CK, Huang ST, Lin CL, Shu KH,
Kao CH. 2016. Risk of cancer in patients with polycystic kidney disease:
a propensity-score matched analysis of a nationwide, population-based
cohort study. Lancet Oncol 17:1419–1425. https://doi.org/10.1016/
S1470-2045(16)30250-9.
53. Sabharwal SS, Schumacker PT. 2014. Mitochondrial ROS in cancer: initi-
ators, ampliﬁers or an Achilles’ heel? Nat Rev Cancer 14:709–721. https://
doi.org/10.1038/nrc3803.
54. Wang W, Karamanlidis G, Tian R. 2016. Novel targets for mitochondrial
medicine. Sci Transl Med 8:326rv323. https://doi.org/10.1126/scitranslmed
.aac7410.
55. Kaspareit-Rittinghausen J, Rapp K, Deerberg F, Wcislo A, Messow C.
1989. Hereditary polycystic kidney disease associated with osteorenal
syndrome in rats. Vet Pathol 26:195–201. https://doi.org/10.1177/
030098588902600302.
56. Loghman-Adham M, Nauli SM, Soto CE, Kariuki B, Zhou J. 2003. Immor-
talized epithelial cells from human autosomal dominant polycystic kid-
ney cysts. Am J Physiol Renal Physiol 285:F397–F412. https://doi.org/10
.1152/ajprenal.00310.2002.
57. Miller FJ, Rosenfeldt FL, Zhang C, Linnane AW, Nagley P. 2003. Precise
determination of mitochondrial DNA copy number in human skeletal
and cardiac muscle by a PCR-based assay: lack of change of copy
number with age. Nucleic Acids Res 31:e61. https://doi.org/10.1093/nar/
gng060.
58. Rooney JP, Ryde IT, Sanders LH, Howlett EH, Colton MD, Germ KE, Mayer
GD, Greenamyre JT, Meyer JN. 2015. PCR-based determination of mito-
chondrial DNA copy number in multiple species. Methods Mol Biol
1241:23–38. https://doi.org/10.1007/978-1-4939-1875-1_3.
59. Edwards JL, Quattrini A, Lentz SI, Figueroa-Romero C, Cerri F, Backus C,
Hong Y, Feldman EL. 2010. Diabetes regulates mitochondrial biogenesis
and ﬁssion in mouse neurons. Diabetologia 53:160–169. https://doi.org/
10.1007/s00125-009-1553-y.
60. Kudin AP, Bimpong-Buta NY, Vielhaber S, Elger CE, Kunz WS. 2004.
Characterization of superoxide-producing sites in isolated brain mito-
chondria. J Biol Chem 279:4127–4135. https://doi.org/10.1074/jbc
.M310341200.
61. Burbulla LF, Krüger R. 2012. The use of primary human ﬁbroblasts for
monitoring mitochondrial phenotypes in the ﬁeld of Parkinson’s disease.
J Vis Exp https://doi.org/10.3791/4228.
62. Kelso GF, Porteous CM, Coulter CV, Hughes G, Porteous WK, Ledgerwood
EC, Smith RA, Murphy MP. 2001. Selective targeting of a redox-active
ubiquinone to mitochondria within cells: antioxidant and antiapoptotic
properties. J Biol Chem 276:4588–4596. https://doi.org/10.1074/jbc
.M009093200.
Mitochondria in ADPKD Cyst Epithelial Cells Molecular and Cellular Biology
December 2017 Volume 37 Issue 24 e00337-17 mcb.asm.org 23
